TickerGuard
Buy Day today: Neutral (51) Mixed market breadth · no major macro event
EXEL

Exelixis Inc

Healthcare · Biotechnology

58.40$ -0.2% vs. previous close Closing price · As of: Sep 18, 2026

Statements

Income Statement

Exelixis Inc (EXEL) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (2025), "Revenue" came in at 2,320 million USD. Tick rows to compare them in a chart.

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Income Statement EXEL
Line item 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
2.3 11 25 41 44 52 53 76 99 113 118 152 185 290 47 31 25 37 191 452 854 968 988 1,435 1,611 1,830 2,169 2,320
-5.7 -19 92 115 129 0.8 1.1 0.8 0.2 281 261 233 183 155 1.1 2.0 3.9 6.6 15 26 33 36 53 58 73 76 84
2.3 16 43 41 44 52 52 75 98 113 118 152 185 290 47 30 23 33 185 437 827 935 951 1,382 1,553 1,758 2,092 2,236
12 22 48 83 112 128 138 141 185 225 257 235 211 157 129 179 189 96 96 112 182 337 548 694 892 1,044 910 825
19 21 28 39 45 37 34 33 33 32 51 51 57 116 159 206 228 293 402 460 503 492 467
18 35 86 110 131 147 159 170 225 307 299 274 244 190 161 230 240 154 212 272 389 565 841 1,095 1,352 1,587 1,488 1,364
-15 -19 -43 -75 -88 -96 -135 -94 -127 -157 -179 -122 -91 90 -122 -201 -224 -121 -28 166 439 369 110 287 201 171 605 872
0.0 0.0 0.0 0.0 0.0 3.7 5.4 6.2 5.0 4.0 6.8 13 9.3 16 27 45 41 41 33 8.7 0.0 0.0 0.0 0.0 54
-16 -81 -85 -85 -95 -137 -95 -101 -86 -163 -141 -92 77 -148 -245 -269 -170 -70 159 452 398 131 294 234 258 682 941
-0.1 32 2.5 0.3 -0.3 31 -9.6 -108 -18 -1.3 -0.1 1.3 0.1 -0.1 -0.2 0.1 32 4.4 -238 77 19 63 52 50 160 159
-16 -19 -75 -71 -86 -95 -137 -84 -101 -86 -163 -135 -92 76 -148 -245 -269 -170 -70 154 690 321 112 231 182 208 521 783
-15 -13 -24 -53 -70 -78 -89 -71 -110 -157 -156 -116 -73 100 -115 -196 -213 -120 -22 167 452 378 119 300 222 283 719 922

Data as of: September 18, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?